Inventiva (IVA) has released an update.
Inventiva reports strong progress in its NATiV3 Phase III clinical trial for lanifibranor, with over 80% enrollment in the main MASH/NASH patient cohort and full enrollment in the exploratory cohort. The company has observed encouraging patient responses, comparable to previous trials, and expects to complete patient visits by the second half of 2024 with topline results by mid-2026. Despite needing additional funding to continue its operations past July 2024, Inventiva has secured a patent extending lanifibranor’s protection until 2043 and is exploring various financing options.
For further insights into IVA stock, check out TipRanks’ Stock Analysis page.
